Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) - Fukuoka, S; Hara, H; Takahashi, N (J Clin Oncol, 2019)